U.S. obesity rates have seen a notable decline, falling to 37% from a peak of 39.9% in 2022, a reduction Gallup attributes to the skyrocketing adoption of GLP-1 agonists for weight loss. The share of Americans reporting GLP-1 use has more than doubled since early 2024 to 12.4%, with women showing higher usage and a faster decline in obesity compared to men. This trend highlights the significant market penetration and public health impact of these pharmaceuticals, even as the reported diabetes rate simultaneously reached an all-time high of 13.8%.
The U.S. obesity rate has seen a significant decline, falling to 37% from a record 39.9% in 2022, representing an estimated 7.6 million fewer obese adults. This reduction is strongly correlated with a dramatic increase in GLP-1 agonist adoption for weight loss, with 12.4% of Americans now reporting usage, more than double the 5.8% reported in early 2024. This indicates a rapid market penetration for these pharmaceutical interventions. Women are leading this trend, showing higher GLP-1 usage at 15.2% compared to 9.7% for men, and experiencing a faster decline in obesity rates (3.5 percentage points vs. 2.3 percentage points since 2022). This demographic divergence suggests targeted marketing or differing access/propensity for treatment among genders, which could influence future market strategies for pharmaceutical companies. Despite the positive trend in obesity reduction, the U.S. diabetes rate simultaneously reached an all-time high of 13.8%, up from 13.4% last year. This divergence highlights the complex nature of public health challenges, suggesting that while GLP-1s are impacting obesity, other factors continue to drive diabetes prevalence or that the impact on diabetes is not yet fully reflected or is offset by other demographic shifts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
